Summary
The nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used medications, particularly in elderly patients, for both rheumatic and nonrheumatic conditions. Elderly patients are more prone to the adverse effects of these agents. Adverse effects are seen in almost every organ system, but the gastrointestinal tract is most frequently affected. Elderly patients are more at risk of adverse effects from a wide range of pharmacokinetic and pharmacodynamic interactions compared with younger patients. By cautious prescribing, including giving due consideration to these factors, the risks associated with NSAIDs in elderly patients can be minimised.
Similar content being viewed by others
References
Adams DH, Howie AJ, Michael J, McConkey B, Bacon PA, et al. Non steroidal anti-inflammatory drugs and renal failure. Lancet 1: 57–60, 1986
Agrawal NM. Making sense of NSAID gastropathy and considering the therapeutic options. Scandinavian Journal of Rheumatology (Suppl. 92): 13–19, 1992
Agrawal NM, Dajani EZ. Options in the treatment and prevention of NSAID-induced gastropathy. Journal of Rheumatology 17 (Suppl. 20): 7–11, 1991
Agrawal NM, Saggioro A. Treatment and prevention of NSAID induced gastroduodenal mucosal damage. Journal of Rheumatology 18 (Suppl. 28): 15–18, 1990
Anderson RJ, Potts DE, Gabow PA, Rumack BH, Shrier RW. Unrecognised adult salicylate intoxication. Annals of Internal Medicine 85: 745–748, 1976
Andreasen PB, Froland A, Skovsted L, Andersen SA, Hauge M. Diphenylhydantoic half life in man and its inhibition by phenylbutazone: the role of genetic factors. Acta Medica Scandinavica 193: 561–564, 1973
Australian Bureau of Statistics. Australian Health Survey 1983. Cat. No. 4311.0 Canberra. Australian Bureau of Statistics, 1986
Benjamin SB, Ishak KG, Zimmerman HJ, Grushka A. Phenylbutazone liver injury: a clinical pathologic survey of 23 cases and review of the literature. Hepatology 1 (3): 255–263, 1981
Bradley J, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of anti-inflammatory dose of ibuprofen, an analgesic dose of ibupfofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. New England Journal of Medicine 325: 87–91, 1991
Brooks PM, Bell MA, Mason DI, Buchanan WW. Interactions of antirheumatic drugs. Agents and Actions 7 (Suppl. 1): 85–89, 1977
Brooks PM, Day RO. NSAID — differences and similarities. New England Journal of Medicine 324 (24): 1716–1725, 1991
Buchanan WW. Implications of NSAID therapy in elderly patients. Journal of Rheumatology 17 (Suppl. 20): 29–32, 1990
Day RO, Brooks PM. Variations in response to NSAID’s. British Journal of Clinical Pharmacology 23: 655–658, 1987
Day RO, Graham GG, Williams KM. Pharmacokinetics of NSAID’s. Bailliere’s Clinical Rheumatology 2 (2): 363–393, 1988
Day RO, Graham GG, Williams KM, Brooks PM. Variability in response to NSAID’s fact or fiction? Current Therapeutics 30: 31–48, March 1989
Day R, Seideman P. NSAIDs, musculoskeletal disorders and gastrointestinal adverse effects. Australian Family Physician 20 (12): 1735–1737, 1991
Department of Community Services and Health. Annual Report 1988/89; Statistical Supplement 48, table 73, September, 1989
Dhand AK, LaBrecque DR, Metzger J. Sulindac (clinoril) hepatitis. Gastroenterology 80: 585–586, 1981
Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM. Methotrexate — nonsteroidal antiinflammatory drug interaction in children with arthritis. Journal of Rheumatology 17: 1469–1473, 1990
Edelson JT, Tosteson ANA, Sax P. Cost Effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. Journal of the American Medical Association 264: 41–47, 1990
Editorial. Topical NSAIDs: a gimmick or a godsend. Lancet 2: 779–780, 1989
Eng J, Sabanathan S. Drug induced oesophagitis. American Journal of Gastroenterology 86: 1127–1133, 1991
Friedman PL, Brown Jr EJ, Gunther S, Alexander RW, Barry WH, et al. Coronary vasoconstrictor effect of indomethacin in patients with coronary artery disease. New England Journal of Medicine 305: 1171–1175, 1981
Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. Journal of Rheumatology 18 (Suppl. 28): 6–10, 1991
Fries JF. Assessing and understanding patient risk. Scandinavian Journal of Rheumatology 92 (Suppl.): 21–24, 1992
Frolich JC, Leftwich R, Raghleb M, Oates JA, Reimann I, et al. Indomethacin increases plasma lithium. British Medical Journal 1: 1115–1116, 1978
Gabriel SE. Is Misoprostol prophylaxis indicated for NSAID induced adverse gastrointestinal events? An epidemiologic opinion. Journal of Rheumatology 18 (7): 958–961, 1991
Geis GS, Stead H, Wallermark CB, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with RA or OA and interim report on prevention by misoprostol of diclofenac associated lesions. Journal of Rheumatology 18 (Suppl. 28): 11–14, 1991
Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibupfofen in the elderly. Arthritis and Rheumatism 25: 1013–1015, 1982
Goulder KJ, Dooley JM, Camfield PR, Fraser AD. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 37: 1392–1394, 1987
Graham GG, Day RO, Champion GD, Lee E, Newton K. Aspect of the clinical pharmacology of antiinflammatory drugs. Clinics in Rheumatic Diseases 10: 229–249, 1984
Greenblatt DJ, Abernethy DR, Matlis R, Harmatz JS, Shader RI. Absorption and disposition of ibuprofen in the elderly. Arthritis and Rheumatism 27: 1066–1069, 1984
Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray W. Non steroidal anti inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Annals of Internal Medicine 114 (4): 257–263, 1991
Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac associated hepatotoxicity. Journal of the American Medical Association 264: 2660–2662, 1990
Hodinka L. Improving the risk-benefit ratio of NSAID therapy in the elderly. Scandinavian Journal of Rheumatology. (Suppl. 91): 3–8, 1991
Houston MC. Non steroidal anti-inflammatory drugs and antihypertensives. American Journal of Medicine 90 (Suppl. 5A): 42S-47S, 1991
Hughes GRV. The problems of using NSAIDs in the elderly. Scandinavian Journal of Rheumatology (Suppl. 91): 19–25, 1991
Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Part I). Drugs & Aging 1: 130–143, 212–227, 1991
Kean WF, Buchanan WW. Variables affecting the absorption of NSAID’s from the gastrointestinal tract. Japanese Journal of Rheumatology 1: 159–170, 1987
Kessler DA. Communicating with patients about their medications. New England Journal of Medicine 325: 1650–1652, 1991
Langman MJS. Ulcer complications and NSAID’s. American Journal of Medicine 84 (Suppl. 2A): 15–19, 1988
March L, Brooks P. Arthritis: the hidden disability. Medical Journal of Australia 158: 369–370, 1993
Marcus F. Pharmacokinetic interactions between digoxin and other drugs. Journal of the American College of Cardiology 5: 82A-90A, 1985
Maton PN. Drug therapy: omeprazole. New England Journal of Medicine 324 (14): 965–975, 1991
Meffin PJ. The effects of renal dysfunction on the disposition of NSAID’s forming acyl-glucuronides. Agents and Actions 17 (Suppl.): 85–89, 1985
Mielants H, De Vos M, Goemaere S, Schelstraete K, Cuvelier C, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases: I. Role of anti-inflammatory drugs. Journal of Rheumatology 18: 389–393, 1991a
Mielants H, De Vos M, Goemaere S, Schelstraete K, Cuvelier C, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases: II. Role of disease. Journal of Rheumatology 18: 394–400, 1991b
Miller TA. Protective agents of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. American Journal of Physiology 245 (5): G601-G623, 1983
O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. Journal of Rheumatology 12: 13–20, 347–353, 562–567, 785–790, 1985
Pond SM, Birkett DJ, Wade DN. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulphenazole. Clinical Pharmacology and Therapeutics 22: 573–579, 1977
Reimann IW, Frolich JC. Effect of diclofenac on lithium kinetics. Clinical Pharmacology and Therapeutics 30: 348–352, 1980
Richardson CJ, Blocka KLN, Ross SG, Verbeek RK. Effects of age and sex on piroxicam disposition. Clinical Pharmacology and Therapeutics 37: 13–18, 1985
Ritch AES, Perera WR, Jones CH. Pharmacokinetics of azapropazone in the elderly. British Journal of Clinical Pharmacology 14: 116–119, 1982
Roberts MS, Rumble RH, Wanwimolruk S, et al. Pharmacokinetics of aspirin and salicylate in elderly subjects and patients with alcoholic liver disease. European Journal of Clinical Pharmacology 25: 253–261, 1983
Rochon PA, Fortin PR, Dear KBG, Minaker KL, Chalmers TC. Reporting of age data in clinical trials of arthritis. Archives of Internal Medicine 153: 243–248, 1993
Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. British Medical Journal 294: 147–150, 1987
Roth SH. NSAID and gastropathy: a rheumatologist’s review. Journal of Rheumatology 15: 912–919, 1988a
Roth SH. Non steroidal anti-intlammatory drugs: gastropathy, deaths and medical practice. (Editorial). Annals of Internal Medicine 109 (5): 353–354, 1988b
Roth SH. Merits and liabilities o fNSAID therapies. Rheumatic Disease Clinics of North America, Vol. 15 (3): 479–498, 1989
Roth SH. Misoprostol in the prevention of NSAID-induced gastropathy. Journal of Rheumatology 17 (Suppl. 20): 20–24, 1990
Roth SH, Bennett RE. Non steroidal anti-inflammatory drug gastropathy: recognition and response. Archives of Internal Medicine 147: 2093–2100, 1987
Rowland M, Riegelman S, Harris PA, Shockoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. Journal of Pharmaceutical Sciences 61: 379–385, 1992
Schlegel SI, Paulus HE. Non-steroidal and analgesic therapy in the elderly. Clinics in Rheumatic Diseases 12 (1): 245–273, 1986
Simon LS. Toxicities of the nonsteroidal anti-inflammatory drugs. Current Opinion in Rheumatology 4: 301–308, 1992
Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. Lancet 1: 1390, 1986
Stillman MT. Interaction and selection of therapeutic agents in the elderly: NSAIDs and the ageing kidney. Scandinavian Journal of Rheumatology (Suppl.) 82: 33–38, 1989
Sweeney KR, Chapron DJ, Brand LJL, Gomolin IH, Feig PU, et al. Toxic interaction between acetazolamide and salicylate. Case reports and pharmacokinetic explanation. Clinical Pharmacology and Therapeutics 40: 518–524, 1986
Szabo S, Piban G. Mechanisms of gastric cytoprotection. Journal of Clinical Gastroenterology 9 (Suppl. 1): 8, 1987
Thyss A, Milano G, Kubar J, Namer M, Scbneider M. Clinical and pharmacokinetic evidence of a life threatening interaction between methotrexate and ketoprofen. Lancet 1: 256–258, 1986
Tonkin AL, Wing LMH. Interactions of NSAID’s. Baillere’s Clinical Rheumatology 2: 455–483, 1988
Velo GP, Milanino R. Nongastrointestinal adverse reactions to NSAID. Journal of Rheumatology 17 (Suppl. 20): 42–45, 1990
Verbeek RK. Pharmacokinetic drug interactions with NSAIDs. Clinical Pharmacokinetics 19 (1): 44–66, 1990
Verbeek RK, Wallace SM, Leewen GR. Reduced elimination of ketoprofen in the elderly is not necessarily due to impaired glucuronidation. British Journal of Clinical Pharmacology 17: 783–784, 1984
Weinblatt ME. Non-steroidal anti-inflammatory drug toxicity: increased risk in the elderly. Scandinavian Journal of Rheumatology 91 (Suppl.): 9–17, 1991
Weinblatt ME, Tesser JR, Gilliam JH. The liver in rheumatic diseases. Seminars in Arthritis and Rheumatism 11: 399–405, 1982
Zarfin Y, Koren G, Maresky D, Perlman M, MacLeod S. Possible indomethacin-aminoglycoside interaction in preterm infants. Journal of Pediatrics 106: 511–513, 1985
Zeidler H. Epidemiology of NSAID induced gastropathy. Journal of Rheumatology 18 (Suppl. 28): 2–5, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Girgis, L., Brooks, P. Nonsteroidal Anti-Inflammatory Drugs. Drugs & Aging 4, 101–112 (1994). https://doi.org/10.2165/00002512-199404020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199404020-00003